## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *  Cohen Yuval  (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]      3. Date of Earliest Transaction (Month/Day/Year)					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director						
C/O COI	RBUS PHA	ARMACEU 500 RIVER	TICALS	11/12/2019	Transactio	on (M	ontn/Day	// Y ear)						
NORWOOD, MA 02062				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	5. Amount of Securities Beneficially Owned Followin Reported Transaction(s) (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
					Code	V	Amoun	(A) or (D)	Price	(mour o u				(Instr. 4)
Common Stock 11/12/20		11/12/2019	P 1,430 A \$ 66,790			D								
Reminder:	Report on a s	eparate line fo		Derivative Securities, you	ies Acquir	Pers cont the f	ons whatained in	no respo n this for splays a	rm are curre	not requesting ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	n 3A. Deemed Execution Da any	4. Transaction Code (Instr. 8)	5.	6. D and (Mo	ate Exerc Expirationth/Day/	cisable on Date	7. T. Amo Und Sect (Inst 4)	Amount or Number of Shares		9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form of Derivat Security Direct ( or Indir	Benefici Ownersh (Instr. 4)

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Cohen Yuval C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	X		Chief Executive Officer			

#### **Signatures**

/s/ Yuval Cohen	11/12/2019
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.